Connect Biopharmaceuticals
- Biotech or pharma, therapeutic R&D
Rademikibart is a best-in-class monoclonal antibody against IL-4Ra with recent positive readouts in both atopic dermatitis and asthma. Connect is actively pursuing global partnerships to accelerate the development and commercialization of rademikibart.
Address
San DiegoCalifornia
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}